PT-141 (Bremelanotide, MW 1025.16 g/mol, CAS 189691-06-3) is a cyclic heptapeptide derived from Melanotan 2 with selective binding affinity at MC3R and MC4R in competitive receptor binding assays. Its MC3R/MC4R selectivity profile distinguishes it from MT-2 in comparative melanocortin receptor pharmacology research.

MC3R and MC4R Binding Research

Receptor Expression Systems

MC3R and MC4R are class A GPCRs expressed in neuronal cell line models and recombinant expression systems. PT-141 is characterised via competitive radioligand binding assays using [125I]-NDP-alpha-MSH as the displacement ligand. Chinese hamster ovary (CHO) cells stably transfected with human MC3R or MC4R provide standardised platforms for binding kinetic studies.

HEK293 cell lines expressing recombinant melanocortin receptors demonstrate consistent receptor density and functional coupling to adenylyl cyclase signalling pathways. Membrane preparations from these expression systems enable detailed pharmacological characterisation of PT-141 binding parameters across multiple experimental conditions.

Binding Affinity Characterisation

Saturation binding experiments establish PT-141's equilibrium dissociation constants (Kd) at MC3R and MC4R subtypes. Competitive binding assays reveal nanomolar to micromolar binding affinities depending on receptor subtype and experimental conditions. The compound demonstrates preferential binding to MC3R over MC4R in direct comparison studies using identical assay protocols.

Kinetic binding studies measure association (kon) and dissociation (koff) rate constants, providing mechanistic insights into receptor-ligand interactions. Temperature-dependent binding experiments reveal thermodynamic parameters governing PT-141-receptor complex formation and stability.

Signalling Pathway Activation

cAMP-Mediated Responses

MC3R and MC4R couple primarily to Gαs proteins, activating adenylyl cyclase and elevating intracellular cyclic adenosine 3',5'-monophosphate (cAMP) concentrations. PT-141 stimulation produces dose-dependent cAMP accumulation in receptor-expressing cell models, with EC50 values determined through non-linear regression analysis.

Forskolin-stimulated cAMP responses provide internal controls for adenylyl cyclase functionality across experimental conditions. Protein kinase A (PKA) activation downstream of cAMP elevation can be monitored through phosphorylation-specific antibodies targeting PKA substrate proteins.

Secondary Messenger Cascades

Beyond cAMP signalling, MC3R and MC4R activation influences calcium mobilisation in certain cell types. Fluorescent calcium indicator dyes enable real-time monitoring of intracellular calcium flux following PT-141 stimulation in appropriate cellular models.

MAPK pathway activation represents an additional signalling branch downstream of melanocortin receptor stimulation. Phospho-ERK1/2 immunoblotting quantifies PT-141-induced kinase activation across various timepoints and concentrations.

Receptor Selectivity Profiling

Melanocortin Receptor Subtypes

PT-141 selectivity across the five melanocortin receptor subtypes (MC1R through MC5R) is established through parallel binding and functional assays. Comparative Ki values reveal receptor subtype preferences, with particular emphasis on MC3R versus MC4R selectivity ratios.

Cross-reactivity screening against related GPCR families ensures specificity of observed responses. Adrenergic, dopaminergic, and serotonergic receptor panels provide negative controls for melanocortin-specific effects.

Structure-Activity Relationships

Peptide backbone modifications and amino acid substitutions influence PT-141's receptor binding profiles. Systematic structure-activity relationship (SAR) studies correlate molecular features with binding affinity and functional potency across melanocortin receptor subtypes.

Conformational analysis through nuclear magnetic resonance (NMR) spectroscopy reveals preferred solution structures that may influence receptor recognition. Molecular docking studies predict binding orientations within melanocortin receptor active sites.

Experimental Methodologies

Cell Culture Systems

Primary neuronal cultures and immortalised cell lines provide complementary platforms for PT-141 receptor pharmacology research. Serum-free culture conditions minimise interference from endogenous melanocortin peptides during binding and functional assays.

Transfection protocols optimise receptor expression levels while maintaining cellular viability and normal signalling responses. Stable cell line generation ensures reproducible experimental conditions across multiple research applications.

Assay Development

Radioligand binding protocols require optimisation of incubation conditions, buffer compositions, and separation techniques. Scintillation proximity assays (SPA) offer homogeneous alternatives to traditional filtration-based binding methods.

High-throughput screening adaptations enable compound library evaluation against melanocortin receptor targets. Automated liquid handling systems ensure precise compound dilutions and consistent assay performance.

Research Summary

PT-141 demonstrates selective binding affinity for MC3R and MC4R melanocortin receptors in recombinant expression systems. The compound activates cAMP signalling pathways and secondary messenger cascades characteristic of Gαs-coupled GPCR responses. Structure-activity relationships reveal molecular determinants of receptor selectivity, while standardised cell culture models provide reproducible platforms for mechanistic studies. These pharmacological properties establish PT-141 as a valuable research tool for investigating melanocortin receptor function and signalling pathway characterisation in controlled laboratory environments.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.